Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBD Biosimilar to Biosimilar Infliximab Switching Study
2018-001546-33Phase 4Completed
- Sponsor
- University Hospital Southampton
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of SB2 in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD), sponsored by University Hospital Southampton. Primary endpoint: Clinical status and drug persistence. Started May 2018; status: completed.
02
Drugs
SB2
03
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2018-001546-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001546-33.